Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

The mass rollout of weight loss injections on the NHS in England began in June. It means GPs are allowed to prescribe the ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

The once-daily pill lowered haemoglobin A1c, a marker for blood glucose control, by an average of 1.3% to 1.6% across doses tested, whilst achieving a 7.9% reduction in average body weight at the ...

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — which accounted for 48% of ...

Diet soda sales are up about 19.5% from 2018, compared to just 8.4% for regular soda in the same period, making it an attractive segment for soda makers seeking growth.

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Find out if Eli Lilly and Co (LLY:XNYS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company's ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

WASHINGTON – Government health officials warned dieters and body builders Friday to immediately stop using Hydroxycut, a widely sold supplement linked to cases of serious liver damage and at least ...